Actelion Ltd. Lifts Profit View On Strong Start For New Drug

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Actelion, Europe's biggest biotech company, raised its 2014 earnings forecast on Tuesday, encouraged by a strong launch for its new heart and lung drug and better-than-expected profit for last year. The Swiss company has seen its prospects brighten after regulators in Europe and the United States approved its big drug hope Opsumit, a treatment for pulmonary arterial hypertension (PAH), at the end of last year. It is banking on Opsumit to cut its dependence on mainstay drug Tracleer, which makes up around 86 percent of sales, but loses patent protection from 2015 and has faced growing competition from Gilead's Letairis.

Help employers find you! Check out all the jobs and post your resume.

Back to news